<DOC>
	<DOC>NCT01855100</DOC>
	<brief_summary>The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.</brief_summary>
	<brief_title>Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9 months, enabling at least 3 months of therapy Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis (DVT)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treatment of acute deep vein thrombosis</keyword>
	<keyword>Prevention of recurrence</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Real-life setting</keyword>
</DOC>